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Our previous studies demonstrated that Ganoderma lucidum polysaccharides (Gl -PS)
exhibit potent immunomodulating effects. Immunomodulation plays an important role
in hematopoiesis. To investigate the possible mechanism by which Gl -PS promote
myelopoiesis during myelosuppression induced by cyclophosphamide, mice were injected
intraperitoneally (i.p.) once daily with 2.5mg/kg of Gl -PS for 10 days and were treated i.p.
once daily with cyclophosphamide (100mg/kg) on days 2 through 4. In the present study
in vivo and in vitro, we ﬁnd that Gl -PS selectively bind to bone marrow stromal cells, stim-
ulate the secretion of hematopoietic growth factors, and enhance the clonogenic activities
of hematopoietic and stromal cells to promote hematopoiesis in myelosuppressed mice.
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INTRODUCTION
Ganoderma lucidum (known in China as Lingzhi and in Japan as
Reishi) is a fungus of the family Polyporaceae that is regarded by
Chinese people as the “miraculous king of herbs” and has attained
a reputation in the East as a beneﬁcial herbal substance. Lingzhi
was ﬁrst indexed as a longevity-promoting and tonic herb of the
non-toxic superior class in the Shen Nong’s Materia Medica (206
BC–8 AD). In clinical trials, G. lucidum exhibits therapeutic efﬁ-
cacy in treating cancer, insomnia, chronic bronchitis, hepatitis,
and leukopenia. Polysaccharides are one of the primary com-
ponents of G. lucidum. Numerous studies have conﬁrmed the
immunoregulatory activities of Ganoderma lucidum polysaccha-
rides (Gl-PS; Lin, 2005; Zhu and Lin, 2006; Zhao et al., 2010).
Cyclophosphamide (Cy), a widely employed alkylating agent and
a major constituent of combination chemotherapy regimens; it
causesmyelosuppression,which limits chemotherapy’s dose inten-
siﬁcation and precludes the administration of optimal treatments
for cancer patients (Bear, 1986).
Prior research has demonstrated that immune cells, such as
T and B lymphocytes, macrophages, and dendritic cells, regu-
late hematopoiesis. Many hematopoietic growth factors (HGF)
are produced by immune cells (Wang et al., 2005). Some HGF
are available for the clinical treatment of myelosuppression
and anemia. However, the use of HGF promotes the entry of
hematopoietic stem cells (HSCs) into the cell cycle, depleting
the supply of HSCs and inhibiting the long-term reconstitution
of hematopoiesis (Homung and Longo, 1992). Previous studies
have indicated that clinical trials applying these growth factors,
such as stem cell factor (SCF), interleukin-3 (IL-3), granulocyte
colony-stimulating factor (G-CSF), and granulocyte-macrophage
colony-stimulating factor (GM-CSF), for bone marrow recovery
after chemotherapy may carry the risk of potentially stimulat-
ing the growth of remaining tumor cells (Pedrazzoli et al., 1995;
Hassan and Zander, 1996; Gutschalk et al., 2006). The use of ery-
thropoietin (EPO) is likely to be restricted in oncology because it
increases the risk of death and serious cardiovascular events (Stein-
brook, 2007). Therefore, it is necessary to search for compounds
that promote hematopoiesis, enhance immunity, potentiate anti-
cancer effects, and detoxify anticancer drugs. Polysaccharides iso-
lated from mushrooms and plants may be a source of beneﬁcial
compounds, as they have been reported to induce hematopoiesis
(Jin et al., 2003; Hatano et al., 2004; Liao et al., 2005).
Immunomodulation plays an important role in hematopoiesis.
Our previous study indicated thatGl-PS stimulate immune cells to
secret cytokines, and restore the bone marrow cells (BMC) counts
and peripheral hemograms reduced by Cy. The beneﬁcial effects
induced by the Gl-PS treatment were not paralleled with any evi-
dent toxic or side effects. (Lin, 2005; Zhu et al., 2007). However, the
effects of Gl-PS on hematopoietic progenitor cells, bone marrow
stromal cells (BMSC), secretion of hematopoietic regulation fac-
tors, apoptosis of the whole BMCs, and bonding pattern, is poorly
understood. Therefore, we investigated the effects of Gl-PS on
regulating hematopoiesis in myelosuppressed mice and explored
their mechanism of regulation.
MATERIALS AND METHODS
ANIMALS AND DRUGS
Male C57BL/6J mice (6–8weeks old) from an inbred strain
were purchased from the Department of Experimental Animals,
PekingUniversityHealth ScienceCenter (PUHSC),Beijing,China.
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The experiments for this study were carried out in accordance
with the Care and Use of Experimental Animals Committee of
PUHSC. G lucidum (Leyss. ex Fr.) Karst. (Lingzhi), cultivated
on wooden logs, was obtained from the G. lucidum Produc-
tion Base in Taining County, Fujian Province in China. The
quality of G. lucidum fruit bodies was monitored by Professor
Mao XiaoLan, a senior researcher of the National Institute of
Microbiology and Microbiological Institute, China Academy of
Science. The suitable G. lucidum strain that was selected for cul-
tivation with wooden logs was Ga0801 (No. of strain), which
was preserved by Professors Shu-Qian Lin and Sai-Zhen Wang
of the Fuzhou Institute of Green Valley Bio-Pharm Technology
in China and identiﬁed by DNA ﬁngerprinting analysis. Gl-PS
were isolated through boiling-water extraction of the fruit bod-
ies of G. lucidum, followed by ethanol precipitation, dialysis,
and protein depletion using the Sevag method. The component
sugars and molecular weight distributions of the glycopeptides
were determined by gel permeation chromatography (GPC) and
high performance liquid chromatography (HPLC). The struc-
tures of the glycopeptides were detected by IR, 1HNMR, and
13CNMR. The isolated Gl-PS are peptide-bound polysaccha-
rides and have a molecular weight of 584,900, with a ratio of
polysaccharides to peptides of 93.61%:6.49%. The polysaccha-
rides consist of d-rhamnose, d-xylose, d-fructose, d-galactose,
d-mannose, d-glucose, and uronic acid, with a molar ratio of
0.793:0.964:2.944:0.167:0.389:7.94:0.33. The glycoside linkage was
primarily in the β-form, with minor α-bonding. The peptides
contain 16 amino acids (Asp, Thr, Ser, Glu, Gly, Ala, Cys, Val,
Met, Ile, Leu, Phe, Lys, His, Arg, and Pro; Lin et al., 2003). The
purity of the Gl-PS is 98%, which was analyzed by HPLC. As a
water-soluble powder, Gl-PS were dissolved in physiological con-
centrations of saline for in vivo experiments or in serum-free
RPMImedium 1640 (Gibco Laboratories,Grand Island,NY,USA)
for in vitro experiments, ﬁltered through a 0.22-μm ﬁlter and
stored at 4˚C for future use. Cy and 5-ﬂuorouracil (5-FU, Shanghai
Hualian Pharmaceutical Co. Ltd., Shanghai,China) were dissolved
in sterilized saline before being injected to mice. Endotoxins in
Gl-PS samples were assayed under endotoxin-free experimen-
tal conditions using a limulus amebocytes lysate chromogenic
assay kit (Beijing BXGK Technology Development Co., Ltd., Bei-
jing, China). The quantity of endotoxin in Gl-PS was less than
0.011 EU/mg, indicating that endotoxin contamination in Gl-PS
was negligible.
LABELING OF GL-PS WITH FLUORESCEIN ISOTHIOCYANATE
Fluorescein isothiocyanate (FITC)–Gl-PS were prepared using a
modiﬁcation of themethod described previously (Thornton et al.,
1996). In short, 20mg of Gl-PS or dextran (MW 70,000, Sigma,
USA) were dissolved in 4ml of 0.1M sodium carbonate, pH 9.0,
mixed with 14mg of (FITC, Sigma Chemical Co., St. Louis, MO,
USA), stirred at room temperature for 4 h while being protected
from light and centrifuged (10,000× g, 1min). The conjugatedGl-
PS were separated from the unbound dye by gel ﬁltration using a
Sephadex G-25 (Pharmacia, NJ, USA) column equilibrated with
phosphate-buffered saline (PBS). The necessary elution fractions
were collected. The concentration of FITC was determined spec-
trophotometrically at 492 nm by a FITC standard curve, and the
polysaccharides concentrationof elution fractionswas determined
using a standard curve of serial-diluted dextran using the phenol–
H2SO4 method. The concentration of FITC–Gl-PS was adjusted
to 1mg/ml.
INDUCTION OF MYELOSUPPRESSION AND TREATMENT REGIME
Mice were divided into three groups: (1) untreated normal con-
trols, (2) mice injected with Gl-PS (2.5mg/kg), and (3) mice
injected with a vehicle (equivalent volume of sterile physiologi-
cal saline) as a negative control. Mice were administered Gl-PS or
vehicle i.p. once daily for 10 consecutive days and were treated i.p.
with Cy (100mg/kg) once daily on days 2 through 4.
PREPARATION OF SPLENOCYTE-CONDITIONED MEDIUM,
GL-PS-SPLENOCYTE-CONDITIONED MEDIUM, AND
PHYTOHEMAGGLUTININ P–SPLENOCYTE-CONDITIONED MEDIUM
Single-cell spleen suspensions were pooled in serum-free RPMI-
1640 medium (Gibco Laboratories, NY, USA) by ﬁltering the
suspension through stainless steel sieves (200 mesh) with the aid
of a glass homogenizer to exert gentle pressure on the spleen
fragments. The splenocytes (1× 107) were cultured in complete
RPMI-1640 medium without splenocyte-conditioned medium
(SCM) or with Gl-PS-splenocyte-conditioned medium (Gl-PS–
SCM) at concentrations ranging from 25 to 200μg/ml, or with
phytohemagglutinin (PHA) at a ﬁnal concentration of 10μg/ml
phytohemagglutinin p–splenocyte-conditioned medium (PHA–
SCM). After 48 h, the respective supernatants were collected and




MACROPHAGE, MEGAKARYOCYTE, AND ERYTHROID (BFU-E)
COLONY-FORMING CELL ASSAY
CFU-Mix, BFU-E, and colony-forming unit-granulocyte–
macrophage (CFU-GM) assays were performed as previously
described (Wang et al., 2005). In brief, the culture system of
CFU-GM consisted of 0.2ml of 0.3% agar, 0.5ml of horse
serum (Hyclone Laboratories, LoganUT,America), 0.2ml of bone
marrow-derived mononuclear cells (BM-MNC; 1× 106 cells/ml),
0.2ml of various SCM or Gl-PS, and 0.9ml of RPMI-1640, which
was plated in 24-well plates (0.5ml/well). After 7 days of culture,
the number of granulocyte and/or macrophage colonies contain-
ing≥50 cellswas countedusing an invertedmicroscope (Olympus,
NY, USA). The total volume of the CFU-Mix and BFU-E culture
systems was 2ml, containing 10% 0.1mM 2-mercaptoethanol,
1% 2mM L-glutamine, 1% bovine serum albumin (BSA), 30%
fetal calf serum (FCS), 2 units erythropoietin (EPO; Sigma, St.
Louis, MO, USA), 20% SCM, 10% BM-MNC (2.5× 106 cells/ml),
and 0.7ml 2.7% methylcellulose in Iscove’s modiﬁed Dulbecco’s
medium (IMDM); this volume was plated into 96-well plates
(0.2ml/well).After seven to 10 days of culture, thenumber of BFU-
E colonies was counted. BFU-E colonies displayed a red color and
burst. After 12 days of culture, the number of CFU-mix colonies
was counted. The CFU-mix was identiﬁed by its ability to form a
mixed colony in which reddish cells (erythroid cells) mixed with
colorless cells (granulocytes, macrophage, and megakaryocyte).
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HIGH PROLIFERATIVE POTENTIAL COLONY-FORMING CELLS ASSAY
As described previously, 5-FU-resistant high proliferative poten-
tial colony-forming cells (HPP-CFCs) were assayed (Wang et al.,
2005). The culture system consisted of 20% FCS, 10% BSA, 40%
IMDM, 10% serum of aplastic anemiamice, 10%BMC (105 cells),
and 10% agar (33 g/L). After 14 days of culture, HPP-CFC were
identiﬁed by their ability to form high proliferative potential
colonies with diameters that were equal to or greater than 0.5mm.
COLONY-FORMING UNIT-FIBROBLAST ASSAY AND PREPARATION OF
CONDITIONED MEDIUM FOR BONE MARROW STROMAL CELLS
The colony-forming unit-ﬁbroblast (CFU-F) assay was carried out
as previously described (Wang et al., 2005). A total of 1× 106 BMC
were incubated in Dulbecco’s Modiﬁed Eagle Medium supple-
mentedwith 10%FCS,10%SCM,and1%penicillin–streptomycin
at 37˚C and 5% CO2. At intervals of 4 days, the cell culture
medium was replaced. After 10 days, the medium was removed,
and the dishes wereWright–Giemsa stained. A ﬁbroblast colony of
greater than 20 cells was scored as a CFU-F.When BMSC achieved
conﬂuence, the conﬂuent cell layers were washed twice with
versene (Ca2+- and Mg2+-free 0.1% ethylenediaminetetraacetic
acid (EDTA) in PBS]. Adherent BMSC were detached with 0.25%
trypsin in versene and seeded at a density of 1× 106 cells/well in
24-well microplates in complete RPMI-1640 medium with Gl-
PS (25–200μg/ml) for 48 h or in an equal volume of serum-free
RPMI-1640 as a control, and supernatants were collected and
stored as small aliquots at −20˚C until use. On day 11 after Gl-PS
administration, BMC in myelosuppressed mice were removed to
evaluate the in vivo effect of Gl-PS on CFU-F formation.
CYTOKINE ASSAY
Cytokines were measured using a sandwich enzyme-linked
immunosorbent assay (ELISA) kit (R&D systems, Minneapolis,
MN, USA) according to the manufacturer’s protocol.
APOPTOSIS ASSAY
Apoptosis of BMC was determined with an Annexin V-FITC
Apoptosis Detection Kit I (Pharmingen, San Diego, CA, USA).
STATISTICAL ANALYSIS
Results were presented as means±SEM of six mice. One-way
analysis of variance (ANOVA) followed by Dunnett’s t -test was
employed. P values below 0.05 were considered signiﬁcant.
RESULTS
EFFECTS OF GL-PS ON THE CLONOGENIC ACTIVITY OF BONE
MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND
STROMAL CELLS IN VITRO AND IN VIVO
Our previous research indicated that, in Cy-induced myelosup-
pressed mice, chronic treatment with Gl-PS (i.p., at 2.5mg/kg)
resulted in the accelerated recovery of BMC and peripheral
hemograms while enhancing the function of immune cells. No
toxic or other side effects were observed in Gl-PS-treated mice
during these experiments (Zhu et al., 2007). To explore the mech-
anism of action of Gl-PS, we designed experiments in vivo and
in vitro. The results of the present study demonstrate that Gl-
PS (2.5mg/kg) promote myelopoiesis in vivo in myelosuppressed
mice, but that directly adding Gl-PS (25–200μg/ml) to cultures
of various hematopoietic progenitor cells had no effect on colony
formation (data not shown). However, the addition of Gl-PS to
SCM increased colony-forming unit counts in vitro. Compared
with the non-stimulation of normal SCM,Gl-PS–SCM treatment
signiﬁcantly promoted the colony formation of CFU-GM, CFU-
Mix, BFU-E, and CFU-F, as observed in vitro (Figure 1). Gl-PS
at a concentration of 100μg/ml attained the maximal effect of
Gl-PS–SCM on CFU-GM (Figure 1), which was higher than that
of the positive control PHA–SCM. PHA–SCM is the source of
colony-stimulating factors, which stimulate splenic mononuclear
cells to secrete severalHGF (Wang et al., 2005).Nevertheless,Gl-PS
and normal SCM alone had no such colony-stimulating activity.
After a 5-FU injection, only a 5-FU-resistant subset of resting stem
cells, termedHPP-CFC, survived.Gl-PS,Gl-PS–SCM, andGl-PS–
medium for bone marrow stromal cells (BMSCM) alone failed to
stimulate HPP-CFC formation in place of serum from aplastic
anemia mice (data not shown). However, Gl-PS–SCM induced
by Gl-PS synergized with the aplastic anemia serum to increased
HPP-CFCcounts (Figure 1). In an in vivo experiment,Gl-PS injec-
tion increased CFU-GM, BFU-E, CFU-Mix, and CFU-F counts in
myelosuppressed mice on day 11 (Figure 2). These results sug-
gest the presence of colony-stimulating factors in Gl-PS–SCM.
Gl-PS promoted myelopoiesis through the indirect stimulation of
HGF secretion, rather than direct stimulation of hematopoietic
progenitor cell proliferation.
CYTOKINES IN GL-PS–SCM, GL-PS–BMSCM, AND SERUM
In in vitro experiments, the production of IL-1, IL-6, GM-CSF,
and G-CSF in Gl-PS–SCM and Gl-PS–BMSCM induced by Gl-
PS for 48 h was signiﬁcant higher than that of normal SCM. In
FIGURE 1 | Effect of Gl -PS and Gl -PS–SCM on the clonogenic activities
of various hematopoietic progenitor cells and stromal cells in bone
marrow in vitro. Splenocytes (1×107) were cultured in complete
RPMI-1640 medium with Gl -PS (Gl -PS–SCM) at various concentrations
(0–200μg/ml) or with phytohemagglutinin (PHA) at a ﬁnal concentration of
10μg/ml (PHA–SCM). After 48 h, the supernatants were collected for
clonogenic assays. Bone marrow cells (BMC, 5×104/well) were plated on
CFU-GM, BFU-E, and CFU-Mix culture systems containing Gl -PS
(0–200μg/ml) alone or Gl -PS–SCM induced by Gl -PS (0–200μg/ml). Colony
numbers were counted (CFU-GM on day 7, BFU-E on day 7–10, and
CFU-Mix on day 12). BMC (105) were collected from 5-FU-treated mice and
were cultured for 14 days in a HPP-CFC culture supplemented with 20%
(v/v) Gl -PS or Gl -PS–SCM. *P<0.05 versus control (concentration of Gl -PS:
0μg/ml). The colony-stimulating activities of PHA–SCM, which served as a
positive control, were 31.4±4.5 for CFU-GM, 12.1±2.6 for BFU-E,
4.5±1.2 for CFU-Mix, 16.2±4.0 for CFU-F, and 21.2±3.5 for HPP-CFC.
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FIGURE 2 | Effects of Gl -SP on the clonogenic activity of various
hematopoietic progenitor cells and stromal cells in the bone marrow
in vivo. On day 11 after Cy treatment, BMC (5×104) were plated on
CFU-GM, BFU-E, and CFU-Mix culture system. *P<0.05 versus the normal
control; #P<0.05 versus the vehicle-administered Cy group.
addition, an increase in SCF levelswas observed inGl-PS–BMSCM
(Table 1). In in vivo experiments, Gl-PS injection increased the
levels of IL-1β, IL-6, G-CSF, and TNF-α, which were undetectable
in normal sera, and IFN-γ in sera derived from myelosuppressed
mice on day 11 (Table 2). Gl-PS stimulated the production of
HGF, including G-CSF, GM-CSF, IL-1, and IL-6 from splenocytes
and G-CSF,GM-CSF, IL-1, IL-6, and SCF from BMSC. These HGF
primarily stimulate myelopoiesis (Wang et al., 2005). IL-3 was
not detected in either Gl-PS–SCM or Gl-PS–BMSCM (data not
shown), and SCF was undetectable in Gl-PS–SCM, which might
be partially due to the absence of a Gl-PS receptor and/or produc-
tion of IL-3 or SCF by the cells in culture. HPP-CFC formation
requires the combined action of SCF, IL-3, GM-CSF, and G-CSF
(Wang et al., 2005). The results suggested that the HGF contained
inGl-PS–SCMandGl-PS–BMSCMsynergizedwith theHGF con-
tained in the serum of aplastic anemia mice to promote HPP-CFC
formation. Gl-PS, normal SCM and BMSCM alone exhibited no
such colony-stimulating activity.
The maintenance of hemopoiesis necessitates a balance
between self-renewal and differentiation into mature blood cells.
A class of cytokines involved in controlling this balance are the
HGF, which stimulate the proliferation and maturation of prog-
enitor cells. Hematopoietic inhibitors inhibit the proliferation of
HSCs and progenitor cells, protect HSCs from excessive differen-
tiation and maintain HSCs in G0/G1 cell cycle stage (Cheng and
Wang, 2002). Studies indicate that HGF, such as IL-1, GM-CSF,
and SCF, accelerate cell entry into S phase, make hematopoietic
cells more vulnerable to cytotoxic agents and cause the deple-
tion of both the number and function of HSCs. Gl-PS injection
increased TNF-α and IFN-γ levels in sera from myelosuppressed
mice (Table 2).We hypothesized thatGl-PS accelerate the recovery
of myelopoiesis after chemotherapy by stimulating the secretion
of IL-1, IL-6, G-CSF, GM-CSF, and SCF to promote hematopoi-
etic precursor proliferation and differentiation and by upregu-
lating negative regulators, such as TNF-α and IFN-γ, to prevent
HSC cycling, resulting in HSC protection and inhibition of HSC
depletion.
FIGURE 3 | Selective binding of FITC–Gl -PS to BMSC. Non-adherent
hematopoietic cells (A,B) and adherent BMSC (C,D) were stained with
FITC-Dextran [negative control (A,C)] or FITC–Gl -PS (B,D) for ﬂow
cytometric analysis. Hematopoietic cells (E) and BMSC (F) stained with
FITC–Gl -PS were also observed under a confocal laser-scanning
microscope.
SELECTIVE BINDING OF GL-PS TO BONE MARROW STROMAL CELLS
Bone marrow stromal cells and non-adherent cells were stained
with FITC–Gl-PS for 1 h at 4˚C. Most of the adherent BMSC,
but not non-adherent hematopoietic cells, were positively stained
by FITC–Gl-PS (Figures 3A–F), suggesting that Gl-PS selectively
bound to BMSC.
EFFECT OF GL-PS ON BMC APOPTOSIS
Bone marrow cells apoptosis was markedly increased after i.p.,
injection of Cy on day 5 during the treatment regime. No differ-
ence in BMC apoptosis was observed between the Gl-PS group
and the vehicle group in myelosuppressed mice (Figure 4).
DISCUSSION
Blood cells and immune cells commonly originate in HSCs.
BMSC possess immunoregulatory activity and are able to support
hematopoiesis. Myeloid hematopoisis, lymphoid hematopoiesis,
and immunoregulation adjacently exist in the hematopoi-
etic inductive microenvironment (Wang et al., 2005). So
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Table 1 | Levels of hematopoietic growth factors in Gl -PS–SCM and Gl -PS–BMSCM.
Concentration of Gl -PS (μg/ml) G-CSF GM-CSF IL-1β IL-6 SCF
Gl -PS–SCM
0 0.0±0.0 5.9±2.3 12.7±4.8 80.3±6.4 0.0±0.0
25 472.6±53.7a 15.0±3.4a 99.5±12.6a 289.2±22.4a 0.0±0.0
50 634.8±82.1a 26.7±4.9a 169.0±14.7a 439.8±41.0a 0.0±0.0
100 801.3±99.2a 38.7±4.6a 281.4±22.5a 635.7±77.0a 0.0±0.0
200 1070.2±123.0a 50.2±6.3a 479.5±40.7a 857.3±104.6a 0.0±0.0
Gl -PS–BMSCM
0 8.0±3.1 3.2±1.5 5.3±3.1 38.2±5.3 20.3±4.1
25 20.8±4.8a 11.5±2.4a 9.5±3.6 155.7±6.9a 43.2±7.5a
50 38.8±7.3a 18.7±4.8a 7.8±3.1 298.8±15.2a 76.0±10.7a
100 71.2±11.2a 49.2±10.3a 8.2±5.2 797.0±33.3a 92.5±13.6a
200 101.7±20.5a 50.7±17.0a 9.0±4.9 922.2±72.2a 155.6±19.5a
Splenocytes (1×107) or bone marrow stromal cells (1×106) were cultured with Gl-PS (0–200μg/ml) for 48 h. Gl-PS-splenocyte-conditioned medium (Gl-PS–SCM)
and conditioned medium of bone marrow stromal cells (BMSCM) induced by Gl-PS were collected to measure cytokines by ELISA.
aP<0.05 versus control (concentration of Gl-PS: 0μg/ml).
Table 2 | Comparison of serum cytokine concentrations (pg/ml) in naive and myelosuppressed mice treated with Gl -PS (i.p., 2.5mg/kg) on day
11.
Groups IL-1β IL-6 G-CSF TNF-α IFN-γ
Normal 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 80.1±20.4
Cy+ vehicle 5.4±2.8a 0.0±0.0 70.5±18.5a 0.0±0.0 67.8±17.9
Cy+Gl -PS 15.6±3.7b 42.1±1.3b 150.7±27.3b 50.4±4.4b 150.5±30.2b
aP<0.05 versus normal control and bP<0.05 versus vehicle control.
FIGURE 4 | Effect of Gl -PS on apoptosis in BMC in myelosuppressed
mice. BMC apoptosis was detected with an Annexin V-FITC test 24 h after
i.p., injection of Cy on day 5 during the treatment regime. **P<0.01 versus
normal.
immunomodulation is closely related to hematopoiesis. Myelo-
suppression and immunosuppression induced by chemoradio-
therapy is a big problem restricting therapeutic effect of tumor.
There is no ideal drug to solve it at present. Therefore, seeking the
drugs that prevent and treat myelosuppression of chemoradio-
therapy for enhancing the therapeutic effect and improving the
prognosis, with no/low toxicity, is challenging.
Our previous studies showed that in cyclophosphamide-
induced myelosuppressed mice, chronic treatment with low-dose
Gl-PS resulted in accelerated recovery of BMC, red blood cells
(RBC), and white blood cells (WBC), while enhancing func-
tion of immune cells (Zhu et al., 2007). In the present study,
we found low-dose Gl-PS promoted myelopoiesis in vivo in
myelosuppressed mice, but adding Gl-PS (25∼ 200μg/ml) to
the colony culture of various hematopoietic progenitors directly,
had no promotive effect on colony formation. However, addition
of Gl-PS–SCM or Gl-PS–BMSCM increased colony formation
of CFU-GM, CFU-Mix, and BFU-E in vitro. Our ﬁndings ﬁrst
demonstrated that most of the adherent BMSC but not non-
adherent hematopoietic cells were positively stained by FITC–
Gl-PS, so Gl-PS speciﬁcally bound to BMSC. BMSC not only
provide the structural scaffolding for hematopoietic cell growth,
but also secrete various HGF to stimulate hematopoiesis (Wang
et al., 2005).
One observation showed that Ganoderma lucidum polysaccha-
ride fraction (GLB) combined with 5-FU decreased the toxicity of
5-FU on BMCs (Liu et al., 2011). Several studies had reported that
Gl-PS had signiﬁcant effects on anti-radiation and leucopoiesis
(Liu et al., 1985; Chen et al., 2000; Wu et al., 2003). In a stem cell
expansion culture, polysaccharide fraction of G. lucidum (F3) pos-
sessed the thrombopoietin (TPO) and GM-CSF like functions to
enhance the survival/renewal abilities of primitive hematopoietic
stem/progenitor cells (Chen et al., 2010). A fraction (F3) of Reishi
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polysaccharides had been shown to activate the expression of IL-1,
IL-6, IL-12, IFN-γ, TNF-α, GM-CSF,G-CSF, andM-CSF inmouse
splenocytes, and from this three subfractions had been prepared
where F3G1 activates IL-1, IL-12, TNF-α, and G-CSF, F3G2 acti-
vates all the cytokines as F3 does, and F3G3 activates only IL-1 and
TNF-α (Chen et al., 2004).
Our research conﬁrmed that CFU-F and CSF production in
BMSC was signiﬁcantly inhibited by Cy, and Gl-PS (2.5mg/kg,
i.p.) signiﬁcantly increased CFU-F formation in bone marrow
from myelosuppressed mice. In our study, Gl-PS stimulated pro-
duction of some HGF including G-CSF, GM-CSF, IL-1, and IL-6
from spleen cells and G-CSF, GM-CSF, IL-1, IL-6, and SCF from
BMSC. These HGF mainly stimulate myelopoiesis.
Primitive hematopoietic stem cell (PHSC) and progenitor cells
in bone marrow have an ability to proliferate and differentiate
into mature blood cells. However, maintenance of haemopoiesis
necessitates a balance between self-renewal on the one side, and
differentiation into the various types of blood cell on the other.
The cytokines involved in controlling this balance are HGF, which
direct the division and maturation of the progenitor cells, and
hematopoietic inhibitory factors,which inhibit PHSC andprogen-
itor cells proliferation,protect PHSC fromexcessive differentiation
in their expansive system, and keep them in G0/G1 cell cycle status
(Cheng andWang, 2002). Our experiments showed that low-dose
injection of Gl-PS increased IL-1β, IL-6, G-CSF, TNF-α, and IFN-
γ levels in sera frommyelosuppressionmice.We hypothesized that
Gl-PS accelerated recovery of hematopoiesis after chemotherapy
by promoting primitive and committed hematopoietic precursors
proliferation induced by HGF secretion on the one hand, and on
the other increasing negative regulatory factors such as TNF-α and
IFN-γ to prevent PHSC cycling resulted in protecting PHSC from
damage.
In conclusion, rather than directly stimulating hematopoietic
progenitor proliferation and inhibition of apoptosis in BMC, Gl-
PS promoted myelopoiesis by selective binding to BMSC which
stimulated HGF secretion to enhance the clonogenic activity of
hematopoietic progenitor cells and improving the hematopoi-
etic microenvironment by enhancing CFU-F formation. Fur-
ther research is necessary to determine whether Gl-PS promote
myelopoiesis by preventing HSC cycling, thereby protecting them
and enhancing the long-term reconstitutionof hematopoiesis after
Cy-induced myelosuppression.
Our ﬁndings may provide a mechanistic basis for using
G. lucidum or Gl-PS as a possible alternative therapeutic
means for lessening chemotherapy-induced myelosuppression via
myelopoiesis potentiation, which needs further study and critical
assessment.
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